Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.880
+0.030 (1.62%)
At close: Nov 14, 2025, 4:00 PM EST
1.850
-0.030 (-1.60%)
After-hours: Nov 14, 2025, 6:23 PM EST
Opus Genetics Employees
Opus Genetics had 18 employees as of December 31, 2024. The number of employees increased by 4 or 28.57% compared to the previous year.
Employees
18
Change (1Y)
4
Growth (1Y)
28.57%
Revenue / Employee
$812,944
Profits / Employee
-$3,789,056
Market Cap
118.53M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | 4 | 28.57% |
| Dec 31, 2023 | 14 | 5 | 55.56% |
| Dec 31, 2022 | 9 | 1 | 12.50% |
| Dec 31, 2021 | 8 | 3 | 60.00% |
| Dec 31, 2020 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IRD News
- 2 days ago - Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease - GlobeNewsWire
- 3 days ago - Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 9 days ago - Opus Genetics Announces $23 Million Registered Direct Offering - GlobeNewsWire
- 9 days ago - Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease - GlobeNewsWire
- 11 days ago - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference - GlobeNewsWire
- 6 weeks ago - Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 - GlobeNewsWire
- 6 weeks ago - Opus Genetics, Inc. - Special Call - Seeking Alpha